Overview

• Oculis Q3 net loss of CHF 16.9 mln, driven by increased R&D expenses

• Company's cash position strengthened to nearly $300 mln post-financing

• Oculis launches PIONEER program for Privosegtor after FDA meeting

Outlook

• Oculis expects DIAMOND Phase 3 trial results for OCS-01 in Q2 2026

• Company plans to initiate Licaminlimab trial in Q4 2025

• Oculis anticipates PIONEER-1 trial for Privosegtor to start in Q4 2025

Result Drivers

• R&D EXPENSES - Increased R&D expenses driven by advancements in clinical development programs, including Phase 3 DIAMOND trials for OCS-01

• FINANCING SECURES TRIALS - Recent financing strengthens cash position to support three pivotal trials in optic neuropathies

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Oculis Holding AG is $36.00, about 46.6% above its November 7 closing price of $19.23

Press Release: ID:nGNEccX1V2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)